Study on the treatment course of Bifidobacterium combined with quadruple therapy including furazolidone and tetracycline for rescue eradication of Helicobacter pylori / 中国综合临床

ABSTRACT

Objective:To explore the effect of the eradication rate and adverse reactions of different courses of Bifidobacterium combined with quadruple therapy containing furazolidone and tetracycline for rescue eradication of Helicobacter pylori.Methods:From December 2016 to May 2019, 348 patients with chronic gastritis who failed to eradicate Hp for the first time were selected from the outpatient department of digestive medicine of Kailuan General Hospital affiliated to North China University of Technology.Group A, B and C were randomly divided by Excel, Group A(116 patients) 14-day quadruple therapy (Eprazole+ colloidal bismuth pectin+ furazolidone + tetracycline); group B(116 patients) Bifidobacterium was given 14 days on the basis of treatment in group A; group C(116 patients) 7 days Bifidobacterium was given in the second week of treatment in group A 4 weeks after the end of eradication treatment, 14 C urea breath test was reexamined, to compare the eradication rate and the incidence of adverse reactions.Results:The eradication rates were 80.2%, 84.5% and 82.3% respectively according to intention treatment.The eradication rates were 88.6%, 90.7% and 89.7%, respectively according to perprotocol.There was no significant difference between the three groups(according to intention to treat analysis: χ 2=0.755, P=0.685; according to the perprotocol analysis: χ 2=0.271, P=0.873). The incidence of adverse reactions in three groups was 16.4%, 6.3% and 7.3% respectively, the difference was statistically significant(χ 2=7.561, P=0.023). Group B was significantly lower than group A(χ 2=5.570, P=0.017), the difference was statistically significant, but there was no statistically significant difference between group C and group A(χ 2=4.362, P=0.037). Conclusion:After 14 days of Bifidobacterium tetrad live tablet assisted with tetrad therapy containing furazolidone and tetracycline, the adverse reactions could be significantly reduced, but Bifidobacterium could not significantly improve the eradication rate.